GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Debt-to-Asset

Hyundai Bioscience Co (XKRX:048410) Debt-to-Asset : 0.10 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Debt-to-Asset?

Hyundai Bioscience Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩5,510 Mil. Hyundai Bioscience Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩24 Mil. Hyundai Bioscience Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₩53,731 Mil. Hyundai Bioscience Co's debt to asset for the quarter that ended in Mar. 2024 was 0.10.


Hyundai Bioscience Co Debt-to-Asset Historical Data

The historical data trend for Hyundai Bioscience Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Debt-to-Asset Chart

Hyundai Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.40 0.19 0.09 0.11

Hyundai Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.10 0.11 0.10

Competitive Comparison of Hyundai Bioscience Co's Debt-to-Asset

For the Biotechnology subindustry, Hyundai Bioscience Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Debt-to-Asset falls into.



Hyundai Bioscience Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Hyundai Bioscience Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5514.103 + 32.432) / 52791.761
=0.11

Hyundai Bioscience Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5509.538 + 24.159) / 53730.675
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyundai Bioscience Co  (XKRX:048410) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Hyundai Bioscience Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co (XKRX:048410) Business Description

Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines